BioScrip (BIOS) Misses Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Needham Starts NeoVolta (NEOV) at Buy
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- SanDisk stock target lifted by Citi on continued demand strength
Jefferies Resumes BioScrip (BIOS) at Buy
November 8, 2016 7:22 AM ESTJefferies resumes coverage on BioScrip (NASDAQ: BIOS) with a Buy rating and a price target of $2.50.
Analyst Brian Tanquilut commented, "We were surprised by BIOS's disappointing Q3 and the resulting guidance cut, and recognize that it further dents the company's already-weak credibility... More
